1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Chengdu Easton Biopharmaceuticals Co., Ltd. Class A

Chengdu Easton Biopharmaceuticals Co., Ltd. Class A

SSSE:688513
45.05
CNY
-1.90
(-4.05%)
1.38EPS
28.43P/E
7.76BMarket Cap
Oct 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.23
1.7
1.87
2.65
3.62
5.81
7.18
6.27
5.81
6.62
6.31
7.71
7.64
7.57
Basic EPS, GAAP
0.11
0.24
0.29
0.45
0.49
1.02
0.82
1.21
1.32
1.39
1.28
1.36
1.63
1.55
Free Cash Flow per Basic Share
-0.36
0.2
0.14
0.69
0.48
0.68
0.35
-0.29
-0.62
-1.06
0.56
0.83
1.03
- -
Dividend per Share
0.02
0.02
- -
- -
0.17
- -
0.17
- -
0.21
0.54
0.4
0.42
0.44
0.93
Book Value per Share
1.19
1.42
1.85
2.95
3.37
4.4
5.27
11.87
12.98
13.85
14.75
15.28
16.61
16.62
Tangible Book Value per Share
1.07
1.3
1.73
2.84
3.25
4.13
5.01
11.68
12.75
13.41
14.27
14.66
14.78
14.79
Basic Weighted Avg Shares
132
123
129
128
131
132
132
147
176
177
177
175
174
174
Sales/Revenue/Turnover
162
209
241
339
476
769
947
922
1,023
1,171
1,117
1,350
1,331
1,320
Operating Margin (%)
8.48
15.07
17.33
11.73
15.53
19.17
11.75
20.64
19.34
19.32
18.55
16.42
18.97
17.09
Depreciation Expense
8
13
20
22
24
25
28
33
33
58
73
83
93
- -
Net Income, GAAP
15
29
38
57
64
135
109
178
232
247
227
238
284
270
Effective Tax Rate (%)
6.72
14.7
14.34
12.51
13.57
8.97
6.3
10.49
5.87
5.9
6.23
5.68
8.7
13.48
Profit Margin (%)
9.07
14
15.63
16.92
13.51
17.56
11.47
19.33
22.72
21.06
20.28
17.65
21.34
20.43
Working Capital
2
14
75
210
277
336
354
1,509
1,347
1,180
1,222
1,332
1,513
1,496
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
40
36
32
29
Total Equity
157
187
244
390
445
582
697
2,095
2,292
2,444
2,603
2,698
3,039
3,022
Return on Invested Capital (%)
- -
11.64
15.43
10.66
15.07
26
16.51
12.46
10.29
10.05
8.41
8.4
9.52
8.28
Return on Capital (%)
- -
14.41
16.62
17.99
15.22
25.89
16.73
12.6
10.47
10.24
8.55
8.57
9.9
9.53
Return on Common Equity (%)
- -
16.96
17.43
18.08
15.42
26.28
16.98
12.76
10.6
10.41
8.98
8.99
10.09
9.47

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
115
50
119
LT Borrowings
32
32
29
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
177
177
177
Market Capitalization
10,866
11,367
7,760

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,132
2,117
2,162
Cash, Cash Equivalents & STI
1,613
1,622
1,673
Accounts Receivable, Net
181
178
167
Inventories
229
247
248
Total Current Liabilities
619
554
666
Payables & Accruals
- -
- -
- -
ST Debt
115
50
119
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
36.36%
7.76%
12.64%
Free Cash Flow
30.49%
28.89%
22.52%
Net Income, GAAP
27.17%
10.56%
19.24%
Sales/Revenue/Turnover
20.36%
8.06%
-1.36%
Total Cash Common Dividend
- -
1,054.61%
3.62%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
315
355
370
310
1,350
2025
306
349
- -
312
1,331
2026
326
333
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.43
0.28
0.4
0.12
1.36
2025
0.34
0.44
- -
0.37
1.63
2026
0.29
0.45
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.16
0.17
- -
0.42
2025
- -
0.43
- -
- -
0.44
2026
- -
0.49
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ming Xu Yuan
Full Time Employees
1,480
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 8, Ankang Road Chengdu SI China 610200
IPO Date
Sep 2, 2020
Website
eastonpharma.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Chengdu Easton Biopharmaceuticals Co., Ltd. focuses its operations on the discovery, development, production, and commercialization of various pharmaceutical solutions. The company delivers comprehensive finished pharmaceutical preparations, encompassing areas such as pain management, cardiovascular health, oncology, and pediatric care. Additionally, it supplies a broad portfolio of active pharmaceutical ingredients across therapeutic categories including oncology, cardiovascular conditions, anesthetics, anti-inflammatory agents, gastrointestinal issues, and neurological disorders. Founded in 2009, this enterprise is strategically located in Chengdu, China.